Steven Bromley, MD
Neurology · Audubon, NJNPI 1962591586
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,328,622 of the $1,540,580 with a category attached, or 86.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.4%. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,543 payments — averaging $434.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$192K
- E.r. Squibb & Sons, L.L.C.$163K
- AbbVie$160K
- Bristol Myers Squibb$124K
- AstraZeneca$119K
- Otsuka America Pharmaceutical, Inc.$110K
- plus $673K from 54 others
Across 16 payments — averaging $9380.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$125K
- Biogen$15K
- Sanofi$10K
What the payments were for
- Consulting fees$75,8625%
- Speaking & faculty fees$1,328,62286%
- Travel & lodging$68,1594%
- Food & beverage$67,2274%
- Education$7090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,540,580 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 27 | $2,858,706 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $391,655 |
| IngrezzaValbenazine Tosylate | 28 | $326,065 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 38 | $301,283 |
| AustedoDeutetrabenazine | 21 | $204,761 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $154,592 |
| BotoxOnabotulinumtoxina | 62 | $88,571 |
| CopaxoneGlatiramer Acetate | 13 | $74,480 |
| AmpyraDalfampridine | 15 | $71,417 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $67,287 |
| UbrelvyUbrogepant | 35 | $48,954 |
| Nurtec OdtRimegepant Sulfate | 28 | $45,776 |
| XeominIncobotulinumtoxina | 38 | $34,900 |
| RytaryCarbidopa/Levodopa | 17 | $33,747 |
| SunosiSolriamfetol Hcl | 11 | $32,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $328 | $391,65528 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $490 | $326,06528 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $743 | $279,24134 claims |
| CSL BehringPrivigen | $108 | $154,59221 claims |
| AbbVieBotox, Ubrelvy | $160,075 | $137,52597 claims |
| Acorda Therapeutics, IncAmpyra | $88 | $71,41715 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $26,352 | $67,28739 claims |
| PfizerNurtec Odt | $4,555 | $45,77628 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $575 | $36,73656 claims |
| Merz North America, Inc.Xeomin | $109 | $34,90038 claims |
| Axsome Therapeutics, Inc.Sunosi | $413 | $32,07211 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $109,715 | $28,57321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Audubon
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
- Andrew SylvesterBridgewater$296K
- Donald BaroneCamden$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.